Lanadelumab for preventing recurrent attacks of hereditary angioedema

Lanadelumab for preventing recurrent attacks of hereditary angioedema (Single Technology Assessment)

As part of the NICE single technology appraisal process, the Aberdeen evidence review group (ERG) critically reviewed the company’s submission related to the clinical and cost-effectiveness of Lanadelumab for preventing recurrent attacks of hereditary angioedema. 

Outcome and Translation

Based on consideration of evidence submitted by the company and the review of the submitted evidence by the Aberdeen evidence review group, NICE recommended Lanadelumab as an option for preventing recurrent attacks of hereditary angioedema in people aged 12 and older. Certain restrictions were applied to the recommendations, full details of which can be found on the NICE website: Lanadelumab for preventing recurrent attacks of hereditary angioedema. Technology appraisal guidance [TA606].

HERU researchers involved in this project: Elisabet Jacobsen and Graham Scotland 

External collaborators: C. Ramsay, M. Brazzelli, E. Cummins and M. Campbell (Health Services Research Unit (HSRU), University of Aberdeen)

Publications

Robertson, C., Walker, A., Jacobsen, E., Aucott, L., Herriot, R., Scotland, G. and Brazelli, M. (2018) Lanadelumab for preventing recurrent attacks of hereditary angioedema, (NICE Technology Appraisal Guidance - TA606), Aberdeen Health Technology Assessment Group.